Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E G De Vries

Showing results (1-10 of 395) with videos related to

Pageof 40
Sort By:
JAMA Oncology|March 10, 2018
Refusing to Become a "Potted Plant"Elisabeth E G de Vries
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 7, 2002
Clinical cancer research 2001: new agents and therapiesJ Verweij, E G de Vries
Nederlands Tijdschrift Voor Geneeskunde|May 29, 1999
[High-dose chemotherapy with stem cell support for solid tumors in adults]S Rodenhuis, E G de Vries
Nederlands Tijdschrift Voor Geneeskunde|December 3, 2003
[Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective]J H Kleibeuker, E G de Vries
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Morpholinyl anthracyclines: option for reversal of anthracycline resistanceE G de Vries, J G Zijlstra
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1989
Mesna: continuous or bolus infusion?P H Willemse, E G de Vries
The Netherlands Journal of Medicine|January 1, 1986
Predicting a patient's response to cancer chemotherapyN H Mulder, E G De Vries
Cancer Treatment and Research|January 1, 1991
Clinical implications of multidrug resistance to chemotherapyE G de Vries, H M Pinedo
Cancer Nursing|August 1, 1987
A patient education program for a continuous infusion regimen on an outpatient basisR Nieweg, J Greidanus, E G de Vries
Lancet (London, England)|August 15, 2001
Relevance of high and low penetranceG J te Meerman, E G de Vries
Pageof 40

Showing results (1-10 of 395) with videos related to

Sort By:
Pageof 40
JAMA Oncology|March 10, 2018
Refusing to Become a "Potted Plant"Elisabeth E G de Vries
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 7, 2002
Clinical cancer research 2001: new agents and therapiesJ Verweij, E G de Vries
Nederlands Tijdschrift Voor Geneeskunde|May 29, 1999
[High-dose chemotherapy with stem cell support for solid tumors in adults]S Rodenhuis, E G de Vries
Nederlands Tijdschrift Voor Geneeskunde|December 3, 2003
[Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective]J H Kleibeuker, E G de Vries
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Morpholinyl anthracyclines: option for reversal of anthracycline resistanceE G de Vries, J G Zijlstra
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1989
Mesna: continuous or bolus infusion?P H Willemse, E G de Vries
The Netherlands Journal of Medicine|January 1, 1986
Predicting a patient's response to cancer chemotherapyN H Mulder, E G De Vries
Cancer Treatment and Research|January 1, 1991
Clinical implications of multidrug resistance to chemotherapyE G de Vries, H M Pinedo
Cancer Nursing|August 1, 1987
A patient education program for a continuous infusion regimen on an outpatient basisR Nieweg, J Greidanus, E G de Vries
Lancet (London, England)|August 15, 2001
Relevance of high and low penetranceG J te Meerman, E G de Vries
Pageof 40